{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:35:43Z","timestamp":1794494143006,"version":"4.9.1"},"reference-count":98,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010888","name":"Wuhan Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clinre.2024.102458","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T12:16:56Z","timestamp":1725279416000},"page":"102458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Gut microbiota\u2013NLRP3 inflammasome crosstalk in metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1016","volume":"48","author":[{"given":"Tingting","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8695-7054","authenticated-orcid":false,"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clinre.2024.102458_bib0001","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2024.102458_bib0002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.clinre.2024.102458_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140908","article-title":"The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis","volume":"10","author":"Anderson","year":"2015","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.clinre.2024.102458_bib0004","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.clinre.2024.102458_bib0005","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.clinre.2024.102458_bib0006","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.31420","article-title":"From NAFLD to MAFLD: implications of a premature change in terminology","volume":"73","author":"Younossi","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.clinre.2024.102458_bib0007","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Hagstr\u00f6m","year":"2024","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.clinre.2024.102458_bib0008","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume":"80","author":"Song","year":"2024","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2024.102458_bib0009","first-page":"691","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.clinre.2024.102458_bib0010","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.it.2017.04.005","article-title":"Evolutionary convergence and divergence in NLR function and structure","volume":"38","author":"Meunier","year":"2017","journal-title":"Trends Immunol"},{"issue":"1","key":"10.1016\/j.clinre.2024.102458_bib0011","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/imr.12285","article-title":"NLRP3 at the interface of metabolism and inflammation","volume":"265","author":"Haneklaus","year":"2015","journal-title":"Immunol Rev"},{"key":"10.1016\/j.clinre.2024.102458_bib0012","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1146\/annurev-pathmechdis-032521-102529","article-title":"Role of the inflammasome in liver disease","volume":"17","author":"de Carvalho Ribeiro","year":"2022","journal-title":"Annu Rev Pathol"},{"issue":"11","key":"10.1016\/j.clinre.2024.102458_bib0013","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-liver axis: pathophysiological concepts and clinical implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cell Metab"},{"issue":"7195","key":"10.1016\/j.clinre.2024.102458_bib0014","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/nature07008","article-title":"A microbial symbiosis factor prevents intestinal inflammatory disease","volume":"453","author":"Mazmanian","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.clinre.2024.102458_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1130562","article-title":"Understanding the role of the gut microbiome in gastrointestinal cancer: a review","volume":"14","author":"A\u011fag\u00fcnd\u00fcz","year":"2023","journal-title":"Front Pharmacol"},{"issue":"23","key":"10.1016\/j.clinre.2024.102458_bib0016","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.3390\/cells11233758","article-title":"NLRP3 and gut microbiota homeostasis: progress in research","volume":"11","author":"Pan","year":"2022","journal-title":"Cells."},{"key":"10.1016\/j.clinre.2024.102458_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2024.118147","article-title":"Paeonol attenuates nonalcoholic steatohepatitis by regulating intestinal flora and AhR\/NLRP3\/Caspase-1 metabolic pathway","volume":"329","author":"Yan","year":"2024","journal-title":"J Ethnopharmacol"},{"issue":"8","key":"10.1016\/j.clinre.2024.102458_bib0018","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.2215\/CJN.04680514","article-title":"How the innate immune system senses trouble and causes trouble","volume":"10","author":"Hato","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.clinre.2024.102458_bib0019","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4049\/jimmunol.0901363","article-title":"Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression","volume":"183","author":"Bauernfeind","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.clinre.2024.102458_bib0020","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural mechanisms of NLRP3 inflammasome assembly and activation","volume":"41","author":"Fu","year":"2023","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"10.1016\/j.clinre.2024.102458_bib0021","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202006194","article-title":"The NLRP3-inflammasome as a sensor of organelle dysfunction","volume":"219","author":"Seoane","year":"2020","journal-title":"J Cell Biol"},{"issue":"6","key":"10.1016\/j.clinre.2024.102458_bib0022","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.immuni.2013.05.016","article-title":"K\u207a efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter","volume":"38","author":"Mu\u00f1oz-Planillo","year":"2013","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.clinre.2024.102458_bib0023","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases [published correction appears in Nat Rev Drug Discov. 2018 Sep;17(9):688. https:\/\/doi.org\/10.1038\/nrd.2018.149]","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.clinre.2024.102458_bib0024","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.clinre.2024.102458_bib0025","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.cell.2014.01.063","article-title":"Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasome activation","volume":"156","author":"Cai","year":"2014","journal-title":"Cell"},{"issue":"64","key":"10.1016\/j.clinre.2024.102458_bib0026","doi-asserted-by":"crossref","first-page":"eabj3859","DOI":"10.1126\/sciimmunol.abj3859","article-title":"NLRP3 inflammasome activation triggers gasdermin D-independent inflammation","volume":"6","author":"Wang","year":"2021","journal-title":"Sci Immunol"},{"issue":"4","key":"10.1016\/j.clinre.2024.102458_bib0027","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1016\/j.jhep.2023.12.009","article-title":"Uric acid may serve as the sixth cardiometabolic criterion for defining MASLD","volume":"80","author":"He","year":"2024","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.clinre.2024.102458_bib0028","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances","volume":"113","author":"Noureddin","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.clinre.2024.102458_bib0029","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.clinre.2024.102458_bib0030","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.clinre.2024.102458_bib0031","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s41423-019-0296-z","article-title":"NLRP3 inflammasome blockade reduces adipose tissue inflammation and extracellular matrix remodeling","volume":"18","author":"Unamuno","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"10.1016\/j.clinre.2024.102458_bib0032","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1124\/pharmrev.122.000629","article-title":"Pharmacological inhibition of the NLRP3 inflammasome: structure, molecular activation, and inhibitor-NLRP3 interaction","volume":"75","author":"Ma","year":"2023","journal-title":"Pharmacol Rev"},{"issue":"10","key":"10.1016\/j.clinre.2024.102458_bib0033","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00109-014-1170-1","article-title":"NLRP3 inflammasome activation is required for fibrosis development in NAFLD","volume":"92","author":"Wree","year":"2014","journal-title":"J Mol Med (Berl)"},{"issue":"5","key":"10.1016\/j.clinre.2024.102458_bib0034","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2024.102458_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110752","article-title":"CXCL5 promotes lipotoxicity of hepatocytes through upregulating NLRP3\/Caspase-1\/IL-1\u03b2 signaling in Kupffer cells and exacerbates nonalcoholic steatohepatitis in mice","volume":"123","author":"Qi","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"18","key":"10.1016\/j.clinre.2024.102458_bib0036","doi-asserted-by":"crossref","first-page":"12966","DOI":"10.1021\/acs.jmedchem.3c00894","article-title":"Novel sulfonylurea-based NLRP3 inflammasome inhibitor for efficient treatment of nonalcoholic steatohepatitis, endotoxic shock, and colitis","volume":"66","author":"Li","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinre.2024.102458_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111565","article-title":"Panaxydol extracted from Panax ginseng inhibits NLRP3 inflammasome activation to ameliorate NASH-induced liver injury","volume":"128","author":"Kim","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.clinre.2024.102458_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111504","article-title":"4-Acetylantroquinonol B ameliorates nonalcoholic steatohepatitis by suppression of ER stress and NLRP3 inflammasome activation","volume":"138","author":"Yen","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.clinre.2024.102458_bib0039","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8294141","article-title":"Plant sterol ester of \u03b1-linolenic acid attenuates nonalcoholic fatty liver disease by rescuing the adaption to endoplasmic reticulum stress and enhancing mitochondrial biogenesis","volume":"2019","author":"Han","year":"2019","journal-title":"Oxid Med Cell Longev"},{"issue":"3","key":"10.1016\/j.clinre.2024.102458_bib0040","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jcmgh.2021.12.002","article-title":"Sphingosine 1-phosphate receptor 4 promotes nonalcoholic steatohepatitis by activating NLRP3 inflammasome","volume":"13","author":"Hong","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2024.102458_bib0041","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3389\/fendo.2018.00640","article-title":"Verapamil ameliorates hepatic metaflammation by inhibiting thioredoxin-interacting protein\/NLRP3 pathways","volume":"9","author":"Zhou","year":"2018","journal-title":"Front Endocrinol (Lausanne)."},{"key":"10.1016\/j.clinre.2024.102458_bib0042","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2147\/JIR.S343236","article-title":"Melatonin suppresses NLRP3 inflammasome activation via TLR4\/NF-\u03baB and P2X7R signaling in high-fat diet-induced murine NASH model","volume":"15","author":"Saha","year":"2022","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.clinre.2024.102458_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105971","article-title":"Dehydromevalonolactone ameliorates liver fibrosis and inflammation by repressing activation of NLRP3 inflammasome","volume":"127","author":"Niu","year":"2022","journal-title":"Bioorg Chem"},{"issue":"4","key":"10.1016\/j.clinre.2024.102458_bib0044","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jhep.2015.11.022","article-title":"Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism","volume":"64","author":"Wan","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2024.102458_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119778","article-title":"Demethylenetetrahydroberberine alleviates nonalcoholic fatty liver disease by inhibiting the NLRP3 inflammasome and oxidative stress in mice","volume":"281","author":"Zhang","year":"2021","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.clinre.2024.102458_bib0046","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1096\/fj.201700602R","article-title":"Silybin inhibits NLRP3 inflammasome assembly through the NAD+\/SIRT2 pathway in mice with nonalcoholic fatty liver disease","volume":"32","author":"Zhang","year":"2018","journal-title":"FASEB J"},{"issue":"58","key":"10.1016\/j.clinre.2024.102458_bib0047","doi-asserted-by":"crossref","first-page":"eabe2933","DOI":"10.1126\/sciimmunol.abe2933","article-title":"Pharmacological targeting of NLRP3 deubiquitination for treatment of NLRP3-associated inflammatory diseases","volume":"6","author":"Ren","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.clinre.2024.102458_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154797","article-title":"A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage","volume":"120","author":"Huang","year":"2021","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.clinre.2024.102458_bib0049","doi-asserted-by":"crossref","first-page":"8795","DOI":"10.3390\/ijms24108795","article-title":"Isoquercitrin attenuates steatohepatitis by inhibition of the activated NLRP3 inflammasome through HSP90","volume":"24","author":"Ma","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.clinre.2024.102458_bib0050","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3390\/md19060318","article-title":"Attenuating effects of dieckol on high-fat diet-induced nonalcoholic fatty liver disease by decreasing the NLRP3 inflammasome and pyroptosis","volume":"19","author":"Oh","year":"2021","journal-title":"Mar Drugs"},{"issue":"1","key":"10.1016\/j.clinre.2024.102458_bib0051","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12906-023-03903-2","article-title":"Protective effecs of baicalin magnesium on non-alcoholic steatohepatitis rats are based on inhibiting NLRP3\/Caspase-1\/IL-1\u03b2 signaling pathway","volume":"23","author":"Guan","year":"2023","journal-title":"BMC Complement Med Ther"},{"issue":"2","key":"10.1016\/j.clinre.2024.102458_bib0052","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00394-020-02305-1","article-title":"S-allylmercaptocysteine improves nonalcoholic steatohepatitis by enhancing AHR\/NRF2-mediated drug metabolising enzymes and reducing NF-\u03baB\/I\u03baB\u03b1 and NLRP3\/6-mediated inflammation","volume":"60","author":"Yu","year":"2021","journal-title":"Eur J Nutr"},{"issue":"1","key":"10.1016\/j.clinre.2024.102458_bib0053","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2226916","article-title":"Neglected gut microbiome: interactions of the non-bacterial gut microbiota with enteric pathogens","volume":"15","author":"Jaswal","year":"2023","journal-title":"Gut Microbes"},{"issue":"1","key":"10.1016\/j.clinre.2024.102458_bib0054","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00018-015-2061-5","article-title":"Gut microbiota and obesity","volume":"73","author":"G\u00e9rard","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.clinre.2024.102458_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodhyd.2023.109068","article-title":"A comprehensive review on food hydrocolloids as gut modulators in the food matrix and nutrition: the hydrocolloid-gut-health axis","volume":"145","author":"A\u011fag\u00fcnd\u00fcz","year":"2023","journal-title":"Food Hydrocoll"},{"issue":"1","key":"10.1016\/j.clinre.2024.102458_bib0056","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41579-020-0433-9","article-title":"Gut microbiota in human metabolic health and disease","volume":"19","author":"Fan","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.clinre.2024.102458_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113430","article-title":"Microbiota alteration and modulation in Alzheimer's disease by gerobiotics: the gut-health axis for a good mind","volume":"153","author":"A\u011fag\u00fcnd\u00fcz","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.clinre.2024.102458_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115788","article-title":"Flavonoids: their putative neurologic roles, epigenetic changes, and gut microbiota alterations in Parkinson's disease","volume":"168","author":"A\u00e7ar","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.clinre.2024.102458_bib0059","doi-asserted-by":"crossref","first-page":"e16225","DOI":"10.15252\/emmm.202216225","article-title":"Targeting gut dysbiosis against inflammation and impaired autophagy in Duchenne muscular dystrophy","volume":"15","author":"Kalkan","year":"2023","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.clinre.2024.102458_bib0060","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2331460","article-title":"Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)","volume":"16","author":"Bened\u00e9-Ubieto","year":"2024","journal-title":"Gut Microbes"},{"issue":"15","key":"10.1016\/j.clinre.2024.102458_bib0061","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.3390\/ijms21155214","article-title":"Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications","volume":"21","author":"Chen","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.clinre.2024.102458_bib0062","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.3390\/nu13082795","article-title":"Effect of diet and dietary components on the composition of the gut microbiota","volume":"13","author":"Beam","year":"2021","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.clinre.2024.102458_bib0063","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.clinre.2024.102458_bib0064","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1021\/acs.accounts.1c00068","article-title":"Imaging commensal microbiota and pathogenic bacteria in the gut","volume":"54","author":"Lin","year":"2021","journal-title":"Acc Chem Res"},{"issue":"8","key":"10.1016\/j.clinre.2024.102458_bib0065","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00018-019-03011-w","article-title":"The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)","volume":"76","author":"Safari","year":"2019","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"10.1016\/j.clinre.2024.102458_bib0066","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","article-title":"Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets","volume":"9","author":"Fleishman","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"10.1016\/j.clinre.2024.102458_bib0067","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.cmet.2019.11.006","article-title":"Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae","volume":"30","author":"Yuan","year":"2019","journal-title":"Cell Metab"},{"issue":"7","key":"10.1016\/j.clinre.2024.102458_bib0068","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.tjnut.2023.05.019","article-title":"Probiotic supplementation, hepatic fibrosis, and the microbiota profile in patients with nonalcoholic steatohepatitis: a randomized controlled trial","volume":"153","author":"Escouto","year":"2023","journal-title":"J Nutr"},{"issue":"4","key":"10.1016\/j.clinre.2024.102458_bib0069","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00394-018-1721-2","article-title":"Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial","volume":"58","author":"Bomhof","year":"2019","journal-title":"Eur J Nutr"},{"issue":"3","key":"10.1016\/j.clinre.2024.102458_bib0070","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3945\/ajcn.113.068890","article-title":"Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study","volume":"99","author":"Eslamparast","year":"2014","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"10.1016\/j.clinre.2024.102458_bib0071","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3390\/nu12040937","article-title":"Randomised double-blind placebo-controlled trial of inulin with metronidazole in non-alcoholic fatty liver disease (NAFLD)","volume":"12","author":"Chong","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.clinre.2024.102458_bib0072","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.759306","article-title":"Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial","volume":"12","author":"Xue","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"10.1016\/j.clinre.2024.102458_bib0073","doi-asserted-by":"crossref","first-page":"6862","DOI":"10.1038\/s41467-022-34671-1","article-title":"Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism","volume":"13","author":"Lei","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.clinre.2024.102458_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2020.108363","article-title":"Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis","volume":"81","author":"Wang","year":"2020","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.clinre.2024.102458_bib0075","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.675267","article-title":"Grape polyphenols attenuate diet-induced obesity and hepatic steatosis in mice in association with reduced butyrate and increased markers of intestinal carbohydrate oxidation","volume":"8","author":"Mezhibovsky","year":"2021","journal-title":"Front Nutr"},{"key":"10.1016\/j.clinre.2024.102458_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.116811","article-title":"Erchen decoction alleviates obesity-related hepatic steatosis via modulating gut microbiota-drived butyric acid contents and promoting fatty acid \u03b2-oxidation","volume":"317","author":"Zhang","year":"2023","journal-title":"J Ethnopharmacol"},{"issue":"12","key":"10.1016\/j.clinre.2024.102458_bib0077","article-title":"Potential therapeutic implications of histidine catabolism by the gut microbiota in NAFLD patients with morbid obesity","volume":"4","author":"Quesada-V\u00e1zquez","year":"2023","journal-title":"Cell Rep Med"},{"issue":"8","key":"10.1016\/j.clinre.2024.102458_bib0078","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.3390\/nu12082340","article-title":"The relationship between choline bioavailability from diet, intestinal microbiota composition, and its modulation of human diseases","volume":"12","author":"Arias","year":"2020","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.clinre.2024.102458_bib0079","first-page":"291","article-title":"Gut microbiota in vascular disease: therapeutic target?","volume":"15","author":"Anbazhagan","year":"2017","journal-title":"Curr Vasc Pharmacol"},{"issue":"11","key":"10.1016\/j.clinre.2024.102458_bib0080","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nri2653","article-title":"Intestinal mucosal barrier function in health and disease","volume":"9","author":"Turner","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.clinre.2024.102458_bib0081","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/gutjnl-2021-326789","article-title":"Gut microbiome and health: mechanistic insights","volume":"71","author":"de Vos","year":"2022","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.clinre.2024.102458_bib0082","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1136\/gutjnl-2020-322260","article-title":"Mucus barrier, mucins and gut microbiota: the expected slimy partners? [published correction appears in Gut. 2023 Nov 24;72(12):e7. https:\/\/doi.org\/10.1136\/gutjnl-2020-322260corr1]","volume":"69","author":"Paone","year":"2020","journal-title":"Gut."},{"issue":"2","key":"10.1016\/j.clinre.2024.102458_bib0083","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41380-022-01841-y","article-title":"Gut microbiota regulates chronic ethanol exposure-induced depressive-like behavior through hippocampal NLRP3-mediated neuroinflammation","volume":"28","author":"Yao","year":"2023","journal-title":"Mol Psychiatry"},{"issue":"1","key":"10.1016\/j.clinre.2024.102458_bib0084","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s40168-019-0733-3","article-title":"Gut microbiota from NLRP3-deficient mice ameliorates depressive-like behaviors by regulating astrocyte dysfunction via circHIPK2","volume":"7","author":"Zhang","year":"2019","journal-title":"Microbiome"},{"key":"10.1016\/j.clinre.2024.102458_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115861","article-title":"NLRP3 inflammasome in hepatic diseases: a pharmacological target","volume":"217","author":"Ramos-Tovar","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.clinre.2024.102458_bib0086","doi-asserted-by":"crossref","first-page":"12200","DOI":"10.1038\/s41598-017-11744-6","article-title":"Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD [published correction appears in Sci Rep. 2017 Dec 11;7(1):17568. https:\/\/doi.org\/10.1038\/s41598-017-17187-3]","volume":"7","author":"Pierantonelli","year":"2017","journal-title":"Sci Rep."},{"issue":"7384","key":"10.1016\/j.clinre.2024.102458_bib0087","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10809","article-title":"Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity","volume":"482","author":"Henao-Mejia","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.clinre.2024.102458_bib0088","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.535940","article-title":"E. coli NF73-1 isolated from NASH patients aggravates NAFLD in mice by translocating into the liver and stimulating M1 polarization","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"10.1016\/j.clinre.2024.102458_bib0089","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12602-017-9378-3","article-title":"Oral administration of compound probiotics ameliorates HFD-induced gut microbe dysbiosis and chronic metabolic inflammation via the G protein-coupled receptor 43 in non-alcoholic fatty liver disease rats","volume":"11","author":"Liang","year":"2019","journal-title":"Probiotics Antimicrob Proteins"},{"issue":"4","key":"10.1016\/j.clinre.2024.102458_bib0090","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s12602-023-10092-4","article-title":"Probiotics, live biotherapeutic products (LBPs), and gut-brain axis related psychological conditions: implications for research and dietetics","volume":"15","author":"A\u011fag\u00fcnd\u00fcz","year":"2023","journal-title":"Probiotics Antimicrob Proteins"},{"issue":"1","key":"10.1016\/j.clinre.2024.102458_bib0091","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/s12967-022-03609-y","article-title":"Recent developments in the probiotics as live biotherapeutic products (LBPs) as modulators of gut brain axis related neurological conditions","volume":"20","author":"A\u011fag\u00fcnd\u00fcz","year":"2022","journal-title":"J Transl Med"},{"key":"10.1016\/j.clinre.2024.102458_bib0092","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.885039","article-title":"Gynostemma pentaphyllum polysaccharides ameliorate non-alcoholic steatohepatitis in mice associated with gut microbiota and the TLR2\/NLRP3 pathway","volume":"13","author":"Yue","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"13","key":"10.1016\/j.clinre.2024.102458_bib0093","doi-asserted-by":"crossref","first-page":"7287","DOI":"10.1039\/D2FO01009G","article-title":"Astragalus mongholicus polysaccharides ameliorate hepatic lipid accumulation and inflammation as well as modulate gut microbiota in NAFLD rats","volume":"13","author":"Zhong","year":"2022","journal-title":"Food Funct"},{"key":"10.1016\/j.clinre.2024.102458_bib0094","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.116145","article-title":"Effects of Tylophora yunnanensis Schltr on regulating the gut microbiota and its metabolites in non-alcoholic steatohepatitis rats by inhibiting the activation of NOD-like receptor protein 3","volume":"305","author":"Lin","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.clinre.2024.102458_bib0095","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2023.1120254","article-title":"Lycopene prevents non-alcoholic fatty liver disease through regulating hepatic NF-\u03baB\/NLRP3 inflammasome pathway and intestinal microbiota in mice fed with high-fat and high-fructose diet","volume":"10","author":"Gao","year":"2023","journal-title":"Front Nutr"},{"issue":"47","key":"10.1016\/j.clinre.2024.102458_bib0096","doi-asserted-by":"crossref","first-page":"14176","DOI":"10.1021\/acs.jafc.1c05596","article-title":"Novel sesquiterpene glycoside from loquat leaf alleviates type 2 diabetes mellitus combined with nonalcoholic fatty liver disease by improving insulin resistance, oxidative stress, inflammation, and gut microbiota composition","volume":"69","author":"Chen","year":"2021","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.clinre.2024.102458_bib0097","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153544","article-title":"Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota","volume":"85","author":"Han","year":"2021","journal-title":"Phytomedicine"},{"issue":"11","key":"10.1016\/j.clinre.2024.102458_bib0098","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1039\/D2FO00012A","article-title":"Walnut green husk ethanol extract improves gut microbiota and their metabolites associated with NLRP3 in non-alcoholic steatohepatitis","volume":"13","author":"Fang","year":"2022","journal-title":"Food Funct"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740124001797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740124001797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T12:33:18Z","timestamp":1732710798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740124001797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":98,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2210740124001797"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2024.102458","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gut microbiota\u2013NLRP3 inflammasome crosstalk in metabolic dysfunction-associated steatotic liver disease","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2024.102458","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102458"}}